Hong Qin

Hong Qin

Auto-generated profile, based on publicly available information

Hong Qin

Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
HQHong Qin
Hong Qin
ZDZhenyuan Dong
Zhenyuan Dong
XWXiuli Wang
Xiuli Wang
WCWesley A. Cheng
Wesley A. Cheng
FWFeng Wen
Feng Wen
LKLarry W. Kwak
Larry W. Kwak
BAFF receptor is a target for CAR T cell therapy of B cell malignancies, circumventing issues with CD19 antigen loss in tumors.

27 November 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HQHong Qin
Hong Qin
GWGuowei Wei
Guowei Wei
ISIppei Sakamaki
Ippei Sakamaki
ZDZhenyuan Dong
Zhenyuan Dong
WCWesley A. Cheng
Wesley A. Cheng
LKLarry W. Kwak
Larry W. Kwak
Purpose: mAbs such as anti-CD20 rituximab are proven therapies in B-cell malignancies, yet many patients develop resistance. Novel therapies against alternative targets are needed to circumvent resistance mechanisms. We sought to generate mAbs against human B-cell–activating factor receptor (BAFF-R/TNFRSF13C), which has not yet been targeted successfully for cancer therapy. Experimental Design: Novel mAbs were generated against BAFF-R, expressed as a natively folded cell surface immunogen on mouse fibroblast cells. Chimeric BAFF-R mAbs were developed and assessed for in vitro and in vivo monotherapy cytotoxicity. The chimeric mAbs were tested against human B-cell tumor lines, primary patient samples, and drug-resistant tumors. Results: Chimeric antibodies bound with high affinity to multiple human malignant B-cell lines and induced potent antibody-dependent cellular cytotoxicity (ADCC) against multiple subtypes of human lymphoma and leukemia, including primary tumors from patients who had relapsed after anti-CD20 therapy. Chimeric antibodies also induced ADCC against ibrutinib-resistant and rituximab-insensitive CD20-deficient variant lymphomas, respectively. Importantly, they demonstrated remarkable in vivo growth inhibition of drug-resistant tumor models in immunodeficient mice. Conclusions: Our method generated novel anti–BAFF-R antibody therapeutics with remarkable single-agent antitumor effects. We propose that these antibodies represent an effective new strategy for targeting and treating drug-resistant B-cell malignancies and warrant further development. Clin Cancer Res; 24(5); 1114–23. ©2017 AACR.

10 October 2023 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
YLYan Luo
Yan Luo
YQYaqing Qie
Yaqing Qie
MGMartha E. Gadd
Martha E. Gadd
AMAlak Manna
Alak Manna
RRRocio Rivera-Valentin
Rocio Rivera-Valentin
HQHong Qin
Hong Qin

25 May 2020 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
ZDZhenyuan Dong
Zhenyuan Dong
WCWesley A. Cheng
Wesley A. Cheng
DSD. Lynne Smith
D. Lynne Smith
BHBrian Huang
Brian Huang
TZTiantian Zhang
Tiantian Zhang
HQHong Qin
Hong Qin
B-cell malignancies can potentially be cured by CD19 chimeric antigen receptor (CAR) T-cell therapy. Although clinical response rates can be up to 93% in acute lymphoblastic leukemia, treatment-related antigen loss and lack of therapeutic persistence contribute to disease relapse. These shortcomings of current CAR T-cell therapy indicate the need for biologically relevant target selection and for improving the efficacy and persistence of the CAR T cells, which we have addressed by developing a novel B-cell activating factor receptor (BAFF-R) CAR T-cell therapy with improved therapeutic persistence. BAFF-R is a B-cell survival receptor and highly expressed in B-cell malignancies. We developed a prototype CAR T cell that efficiently and specifically eliminated BAFF-R expressing human B-cell tumors in several xenogeneic mouse models, including models of CD19 antigen loss. We proceeded with translational development and validation of BAFF-R CAR T cells produced under current good manufacturing practices (cGMP). cGMP-grade BAFF-R CAR T cells underwent in vitro and in vivo validation in established models to confirm that the potency and efficacy of our original research modeling was replicated. Food and Drug Administration required release testing was performed to ensure our BAFF-R CAR T cells meet specifications for new drug products. Completing and exceeding these requirements, the data fully support the initiation of a first-in-human Phase 1 trial for BAFF-R-positive relapsed/refractory (r/r) B-ALL.

1 October 2011 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
PDF file
FYFang Yu
Fang Yu
XZXiudan Zhu
Xiudan Zhu
FCFeng Chen
Feng Chen
TWTianyou Wang
Tianyou Wang
QHQin Hong
Qin Hong
STSuoqin Tang
Suoqin Tang

5 October 2024 in Molecular Therapy Oncology
Verified
Journal Article
Open access
YLYan Luo
Yan Luo
MGMartha E. Gadd
Martha E. Gadd
YQYaqing Qie
Yaqing Qie
AOAndrea Otamendi-Lopez
Andrea Otamendi-Lopez
JSJesus E. Sanchez-Garavito
Jesus E. Sanchez-Garavito
HQHong Qin
Hong Qin
Chimeric antigen receptor (CAR) T cell therapy has encountered limited success in solid tumors. The lack of dependable antigens and the immunosuppressive tumor microenvironment (TME) are major challenges. Within the TME, tumor cells along with immunosuppressive cells employ an immune-evasion mechanism that upregulates programmed death ligand 1 (PD-L1) to deactivate effector T cells; this makes PD-L1 a reliable, universal target for solid tumors. We developed a novel PD-L1 CAR (MC9999) using our humanized anti-PD-L1 monoclonal antibody, designed to simultaneously target tumor and immunosuppressive cells. The antigen-specific antitumor effects of MC9999 CAR T cells were observed consistently across four solid tumor models: breast cancer, lung cancer, melanoma, and glioblastoma multiforme (GBM). Notably, intravenous administration of MC9999 CAR T cells eradicated intracranially established LN229 GBM tumors, suggesting penetration of the blood-brain barrier. The proof-of-concept data demonstrate the cytolytic effect of MC9999 CAR T cells against immunosuppressive cells, including microglia HMC3 cells and M2 macrophages. Furthermore, MC9999 CAR T cells elicited cytotoxicity against primary tumor-associated macrophages within GBM tumors. The concept of targeting both tumor and immunosuppressive cells with MC9999 was further validated using CAR T cells derived from cancer patients. These findings establish MC9999 as a foundation for the development of effective CAR T cell therapies against solid tumors.